Comparing Avivagen (OTCMKTS:VIVXF) & 5N Plus (OTCMKTS:FPLSF)

5N Plus (OTCMKTS:FPLSFGet Free Report) and Avivagen (OTCMKTS:VIVXFGet Free Report) are both small-cap basic materials companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.


This table compares 5N Plus and Avivagen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
5N Plus 2.08% 7.14% 2.47%
Avivagen -645.05% N/A -716.72%

Earnings & Valuation

This table compares 5N Plus and Avivagen’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
5N Plus $264.22 million 1.09 -$23.00 million $0.06 54.34
Avivagen $730,000.00 0.44 -$4.71 million ($0.04) -0.10

Avivagen has lower revenue, but higher earnings than 5N Plus. Avivagen is trading at a lower price-to-earnings ratio than 5N Plus, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

0.1% of 5N Plus shares are held by institutional investors. 3.9% of 5N Plus shares are held by company insiders. Comparatively, 2.1% of Avivagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for 5N Plus and Avivagen, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
5N Plus 0 0 0 0 N/A
Avivagen 0 0 0 0 N/A

5N Plus currently has a consensus price target of $5.50, indicating a potential upside of 68.71%. Given 5N Plus’ higher probable upside, analysts plainly believe 5N Plus is more favorable than Avivagen.

Risk & Volatility

5N Plus has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, Avivagen has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500.


5N Plus beats Avivagen on 11 of the 12 factors compared between the two stocks.

About 5N Plus

(Get Free Report)

5N Plus Inc. produces and sells specialty metals and chemicals in North America, Europe, and Asia. It operates through Specialty Semiconductors and Performance Material segments. The company offers semiconductor compounds, semiconductor wafers, metals, epitaxial semiconductor substrates, and solar cells. It also provides active pharmaceutical ingredients, animal feed additives, specialized chemicals, commercial grade metals, alloys, engineered powders, and recycling services. The company serves renewable energy, security, space, pharmaceutical, medical imaging, manufacturing, electronic, consumer, and industrial application markets. 5N Plus Inc. is headquartered in Montreal, Canada.

About Avivagen

(Get Free Report)

Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.

Receive News & Ratings for 5N Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 5N Plus and related companies with's FREE daily email newsletter.